Valeant Pharmaceuticals International Inc. is in the midst of a hard sell on how it’s changed its corporate culture now that former CEO Michael Pearson and many of his fellow board members have left the company. Valeant’s proxy statement to shareholders, which arrived in mailboxes in recent days, is part of the effort, what with its listing of “shareholder-friendly compensation practices” and a passage about all the dialogue it’s had with investors in the last year or so.
Discover content from The Globe and Mail that you might otherwise not have come across. Here we’ll provide you with fresh suggestions where we will continue to make even better ones as we get to know you better.
You can let us know if a suggestion is not to your liking by hitting the ‘’ close button to the right of the headline.